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This editorial refers to ‘Impact of right ventricular reserve
on exercise capacity and survival in patients with pulmonary
hypertension’, by F.C. Blumbergetal., published in this issue
on pages 771–775.
Pulmonary arterial hypertension (PAH) and chronic thrombo-
embolic pulmonary hypertension (CTEPH) are rare conditions asso-
ciated with apoorprognosis, forwhich treatments areexpensive and,
at best, only moderately efficacious. Until the very latest stages of
disease progression, symptoms occur almost exclusively with physic-
al exertion, most probably reflecting insufficient oxygen delivery to
peripheral muscles caused through limitations of right ventricular
(RV) reserve relative to heightened pulmonary vascular afterload.1
Despite this, assessments are most frequently performed at rest. In
this issue of the journal, Blumberg and colleagues2 remind us that
resting measures may be an inadequate surrogate of the pathophysi-
ology of pulmonary hypertension when assessed during exercise.
They performed cardiopulmonary testing and cardiac catheteriza-
tion at rest and during exercise in 21 PAH and 15 CTEPH patients,
and observed a modest correlation between cardiac index during
exercise and maximal oxygen uptake (peakVO2). This is not greatly
surprising as cardiac output is known to explain the majority of vari-
ance in VO2 in health and disease
3—put simply, if the blood cannot
get to the muscles then it cannot be utilized. Of greater interest is
the finding that the strongest predictors of survival were all obtained
during exercise. Peak cardiac index and the pressure/flow relation-
ship (analogous to the change in pulmonary vascular resistance)
both predicted survival (61% at 5 years), while the strongest predic-
tors were the non-invasively determined measures of peakVO2 and
ventilatory efficiency (VE/VCO2).
These findings are consistent with previous experience. In a larger
cohort, Wensel et al.4 demonstrated that peakVO2 was a strong
predictor of survival in patients with PAH, especially when systolic
blood pressure failed to increase during exercise. As compared
with cardiopulmonary testing, a 6 min walk distance (6MWD) is a
simpler measure of exercise capacity that may be nearly as accurate
in predicting patientoutcomes.5 Partly as a result of this simplicity, the
6MWD has been adopted as the primary endpoint for multiple clin-
ical trials investigating the efficacy of various pulmonary vasodilators.
This would seem reasonable given that 6MWD is a practical descrip-
tion of functional capacity (an important treatment goal) and the cor-
relationbetween6MWDandsurvival suggests utility as a surrogateof
improved patient outcomes. However, recent analyses of pooled
PAH patient data suggest that the 6MWD fails on both counts,6,7
leaving us to ask why. The agreement between 6MWD and
peakVO2 is relatively poor,
8 and perhaps the 6MWD is just too
blunt a measure to detect meaningful differences in exercise capacity
after only 3–4 months of therapy. Blumberg et al. did not assess
6MWD, but their data would suggest that well-performed exercise
measures should not be dismissed. On the contrary, cardiopulmon-
ary andhaemodynamicmeasureswereonlyofprognostic valuewhen
measured during exercise and thus we may conclude that the goal
should be to sharpen our exercise measures further.
If surrogate measures are to be chosen as endpoints in PAH trials,
then it is clearly desirable that they offer an insight into the patho-
physiology of the condition and the mechanism of therapeutic
effect.9 In this regard, the methodologies described by Blumberg
et al.2 and Groepenhoff et al.10 enable some separation of pulmonary
vs. systemic vascular vs. cardiac factors, and represent a clear advance
on the 6MWD. However, significant limitations remain. Cardiopul-
monary and thermodilution measures provide a very indirect
summary of cardiac function which provides little insight into
whether limitation is primarily due to RV or LV impairment of
filling or ejection. Until recently, accurate assessment of biventricular
function during exercise has been a major challenge, but real-time
cardiac magnetic resonance offers unprecedented accuracy in deter-
mining changes in cardiac volumes,11 and these techniques have been
used by Holverda et al. to describe elegantly the cardiac limitations of
PAHpatients1 (and exemplified in Figure 1). The quantificationof ven-
tricular volumes in combination with intracardiac pressure measures
during exercise would provide the ultimate gold standard in which
true appraisal of ventriculo-arterial interactions could be appraised
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while simulating the physiological stressors at the time when symp-
toms are manifest. Such assessments may provide increased power
to detect treatment-related differences in cardiopulmonary function
and, moreover, are likely to provide invaluable insights into the
mechanisms of action of novel and established treatments. A simul-
taneous assessment of RV function and pressures may, for example,
explain why Blumberg et al. observed a poor correlation between
mean pulmonary artery pressures and peakVO2.
2 This differs from
the experience in healthy subjects in which a near linear relationship
between pulmonary arterial pressures and exercise capacity/VO2/
cardiac output has been well demonstrated.12–14 In congestive
heart failure patients, Lewis et al. demonstrated that a rapid increase
and early plateau in pulmonary arterial pressures portended a
particularly poor prognosis.14 Thus, patients with relatively low pul-
monary vascular resistance and good RV function may have similar
exercise pulmonary arterial pressures to those patients with high
pulmonary vascular resistance and decompensated RV function.
The distinction is important and can only be made if there is simultan-
eous assessment of both RV function and pressures.
Pulmonary arterial hypertension is rare, and the pathophysiologic-
al implications of disease progression remain incompletely under-
stood. The data of Blumberg et al.2 remind us of the importance of
studying our patients during exercise, when symptoms and physio-
logical limitations are most appreciable. Their data challenge us to
assess whether more accurate exercise measures will provide even
greater insights into the pathophysiology of PAH and more specific
measures against which treatment efficacy may be assessed.
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Figure1 Real-time exercise cardiac magnetic resonance imaging
demonstrating increasing right ventricular dilation and dysfunction
during exercise in a patient with pulmonary hypertension. Short-
axis images acquired at a mid-ventricular level in a subject with
chronic thrombo-embolic pulmonary hypertension describing pro-
found breathlessness and pre-syncope with exertion. End-systolic
images demonstrate a moderately dilated right ventricle with mild
systolic dysfunction at rest (upper panel) becoming more dilated
duringnear-maximal exercise (lower), resulting infilling impairment
of the left ventricle and markedly attenuating increases in cardiac
output. Thus, as compared with rest, the exercise pathophysiology
better explains the severity of the symptoms.
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